Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

OBJECTIVES: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. METHODS: Existing...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Kerschbaumer, Andreas, Dörner, Thomas, Dougados, Maxime, Fleischmann, Roy M, Geissler, Klaus, McInnes, Iain, Pope, Janet E, van der Heijde, Désirée, Stoffer-Marx, Michaela, Takeuchi, Tsutomu, Trauner, Michael, Winthrop, Kevin L, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Boehncke, Wolf-Henning, Emery, Paul, Isaacs, John D, Kremer, Joel, Lee, Eun Bong, Maksymowych, Walter P, Voshaar, Marieke, Tam, Lai-Shan, Tanaka, Yoshiya, van den Bosch, Filip, Westhovens, René, Xavier, Ricardo, Smolen, Josef S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Recommendation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788060/
https://www.ncbi.nlm.nih.gov/pubmed/33158881
http://dx.doi.org/10.1136/annrheumdis-2020-218398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788060/
https://www.ncbi.nlm.nih.gov/pubmed/33158881
http://dx.doi.org/10.1136/annrheumdis-2020-218398

Ejemplares similares